Home • SuperSonic Imagine • Supervisory Board

Supervisory Board



Hermann Requardt

Hermann Requardt, Chairman of the Board, appointed in October 1st 2015, spent most of his carreer in Siemens Healthcare where he recently served as CEO.

Dr. Requardt is an Honorary Professor of Physics at the Goethe University in Frankfurt and serves on several academic and industrial boards. He most recently served as Chief Executive Officer of Siemens Healthcare from 2009 to February 2015. Prior to that, he was Chief Technology Officer of Siemens AG since 2008. He began his career in 1984 as a physicist within Siemens Medical Solution’s Imaging division. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt.




MB portrait1



Michael Brock

Michael Brock, Vice Chairman of the Supervisory Board of SuperSonic Imagine, was the CEO of the Danish company BK Medical, a leader in ultrasound technology in the area of urology and surgery.

Mr. Michael Brock had been Managing Director and President of B-K Medical A/S at Analogic Corporation and also served as its Chief Executive Officer. Previously, he served as President of GN Otometrics, a subsidiary of GN Resound A/S. In 1979, he joined Bruel & Kjaer, the original parent company of B-K Medical, where he headed the Sales & Marketing Group covering the entire Sound & Vibration segment. He  was subsequently promoted to President of the Sound & Vibration Division, and was later appointed President of the Environmental and Transducer Divisions as well. In 1997, Mr. Brock joined the GN Group as President of Madsen Electronics A/S, a smaller company within the Audiologic Measuring Equipment business. Under his aegis, the company developed into the world's leading manufacturer of diagnostic hearing and balance instrumentation and software. In 2001, Madsen Electronics was renamed GN Otometrics A/S, one of GN's four core business areas today.

Mr. Brock holds a Master of Science degree in Electronic Engineering, Acoustics, from the Technical University of Denmark.









Philippe Boucheron

Philippe Boucheron is the co-founder Bioam Funds. He sits on the board of several Biotech of Medtech companies.

Between 1993 and 1996, Philippe Boucheron worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare.
From 1997 to 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris. Here, he spent a significant part of his time following French and European listed biotech companies. In 2000, he co-founded the Bioam Funds dedicated to early-stage life science investments and became Investment Manager, then in 2004 Managing Partner.
After the merger of Bioam with CDC entreprises in July 2010, Philippe Boucheron joined the CDC Entreprises life sciences' team as Investment Manager.
In 2013, CDC Entreprises, FSI and Oséo merged to create Bpifrance. Since then, he is deputy chief of the Life Investments BU and sits on Bpifrance Investissement's Investment Committee. Philippe Boucheron also sits on the boards of Ademtech, Integragen, SSI, Advicenne, ART, GamaMabs and CorWave. Philippe Boucheron holds an engineering degree in Biochemical Engineering and Microbial genetics from the Institut National des Sciences Appliquées in Toulouse, a MSc in Biochemical Engineering from the Ecole Polytechnique.



Bernard Doorenbos



Bernard Doorenbos

Bernard Doorenbos spent most of his career in senior management in listed companies such as Axxicon Group, Neways Electronics and Vilenzo International.

Management Board of Vilenzo International N.V. since December 15, 2003. Mr. Doorenbos served as Chief Executive Officer of Neways Electronics International N.V.

Bernard Doorenbos began as an officer in the Royam Netherland Navy. He then joined Phillips Group’s Medical Systems division, in 1983, where he was Head of Sales and Services for Latin America, and then joined Thalès’ naval division in 1986. Following his impressive performance, Bernard Doorenbos has since spent most of his career in senior management in listed companies such as Axxicon Group, Neways Electronics and Vilenzo International, as well as at the helm of a number of industrial companies.

Bernard Doorenbos, 66, has an MSc in Electronics from the Delft University of Technology and a Master’s degree in Financial Economics from the University of Amsterdam.




Olivier Litzka

Olivier Litzka joined Edmond de Rothschild Investment Partners’ (EdRIP) as a partner in 2006. He invests in Biotechnology and Medtech companies mainly in Europe, but also selectively in the US.

Olivier serves on the boards of Noxxon Pharma (Berlin), Endosense (Geneva), JenaValve (Munich), and Probiodrug (Halle), as well as SuperSonic Imagine.  Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France).

Before joining EdRIP, Olivier spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting, both in Munich and Paris.

Olivier holds a PhD in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and performed his scientific research work over several years in Munich and Oxford.



Sabine Lochmann

Sabine Lochmann

Managing Director, BPI Group.
Sabine Lochmann has a dual French-American legal background. She is a graduate of Paris 1 Panthéon-Sorbonne and the University of Davis, California (LLB in business law). Additionally, Sabine completed an Executive Leadership Program in South Africa (University of Cape Town).

Sabine began her career as a lawyer focused in the services sector, working with Jacobs Serete and JC Decaux before taking direction of the legal department of Johnson & Johnson France in 1998.  
In 2008, she accepted a new career challenge in, assuming the role of Marketing Director at Johnson & Johnson, followed by General Director in charge of Market Access, and then General Director of government and strategic affairs in 2010.
She is also actively involved in a number of professional organizations, including “Juristes d’Entreprise” (AFJE), of which she served as President from 2001 to 2005. She also served as Vice President of the European Confederation of business lawyers (ECLA) from 2003 to 2006.
Sabine has also founded several think-tanks, including “Avenir Femmes Santé” in 2011, dedicated to women’s health issues, and the “Ateliers de la Convergence” in January 2012, bringing together business leaders, social partners, and HR specialists on the subject of competitiveness, employment, and legal issues. Since April 2013, she had joined Supersonic Imagine as Independent board Director.

Sabine joined BPI group as Managing Director in 2014, and focuses on commercial development in France and internationally.




Alexia Perouse

Alexia Perouse has a mix Neurosciences & Management of Enterprise background and joined the venture capital field in 1999. Partner at Omnes Capital, she invests in Life science and  has developed the Medical Device portfolio.

Alexia Perouse has particularly followed the companies Biolipox (merged with Orexo in 2007) and Mutabilis (sold to Pharma Omnium International in 2009).
She has invested in Fovea Pharmaceuticals (sold to Sanofi Aventis in 2009). In addition of her investment in SuperSonic Imagine since the Serie A, she has developed the Medtech portfolio through numerous investments in Cellnovo, CircuLite, Eos Imaging, EyeTechCare, SpineGuard and Stentys (IPO in 2010). She currently sits at 6 boards.

Before joining the venture capital within Sofinnova Partners and then  CAPE in 2005, Alexia Perouse has carried out missions of consulting & business development at Parteurop Développement for biotech start-ups. She started her career as an analyst at Chiron Vaccines.




François Valencony

Francois Valencony started his work experience within Schneider Electric in the USA, supporting several acquisitions and growth projects for the North American division until 2000. He then actively participated in the build-up of a start-up IT company out of London in 2000, subsequently acquired by Descartes group.

François has been working for Institut Merieux since 2003, leading several transactions for the group, including an exclusive license agreement between Roche and Transgene in 2007 and a structured option with Novartis on a Phase IIB drug candidate. Operational responsibilities included the set-up of the first research center of bioMerieux in China, focusing on emerging pathogens and the project management of 5 vaccine programs in the field of infectious diseases and oncology. Francois is currently General Manager of Merieux Développement, the private equity arm of Institut Merieux focusing on healthcare investments. François graduated from HEC in Paris and holds a Master Degree from CEMS out of Köln, Germany.